Lunsumio VELO

The FDA has approved Lunsumio VELO™, a subcutaneous formulation, for relapsed or refractory follicular lymphoma patients who have failed two or more prior therapies. This novel treatment offers a significantly reduced administration time, transforming from a hours-long infusion to a one-minute injection. This advancement aims to decrease patient burden and increase treatment flexibility, with a fixed-duration schedule potentially as short as six months. The approval is based on promising efficacy data, including a high objective response rate and a manageable safety profile, with ongoing research exploring its use in earlier lines of therapy.